Upregulated expression of transcription factors promoting cone identity in late-stage retinal progenitors drives development ...

Robin “Shyne” Edwards is building more than a brand; she’s cultivating a community rooted in access, visibility, and empowerment. As the founder of Noir, Edwards is reshaping how technology, ...

As of April 2025, four CD19-directed chimeric antigen receptor (CAR)-T therapies and three CD20-targeting bispecific antibodies (BsAbs) have been US Food and Drug Administration (FDA) approved for the ...

The 1st CIG's greatest expertise lies in precisely locating American hostages held by foreign terrorist groups and ...

About 70 people gathered at City Hall on Jan. 21 to weigh in on some "big ideas" for making downtown Anacortes safer and more ...

Neoantigens are unique markers that distinguish only cancer cells. By adding B cell reactivity, cancer vaccines can move beyond one-time attacks and short-term memory to become a long-term immunity ...

– New collaboration builds on Sanofi’s prior acquisition of DR-0201 and further leverages Dren Bio’s proprietary Targeted Myeloid Engager and Phagocytosis Platform to discover first-in-class ...

This work reveals metabolic pathways and molecular events mechanistically linked to B cell activation. Using an unbiased, comprehensive proteome profiling method and various functional validation ...

Cabaletta Bio’s CAR-T cell therapy has eliminated the overreactive B cells of two patients with an autoimmune disease without preconditioning chemotherapy, pleasing investors and analysts while ...

DuoCAR20.19.22-D95 targets CD19, CD20, and CD22, addressing antigen escape in B-cell malignancies like B-ALL and B-NHL. Early-stage trials show no safety concerns for DuoCAR20.19.22-D95, with ongoing ...